68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors - ND
- Conditions
- Study of tumor neuroendocrin origin
- Registration Number
- EUCTR2010-022975-67-IT
- Lead Sponsor
- AZIENDA U.L.S.S. N.8 DI ASOLO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Adult subjects (male and female) with recent diagnosis of neuroendocrine tumors (such as carcinoid and GEP tumors) before treatment.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Normal volunteers, young people, pregnant women.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): Compare the percentage of patients identified with positive CT scan showing the percentage of patients identified themselves with positive PET;Main Objective: To assess the role of 68Ga-DOTANOC PET in the diagnosis of neuroendocrine tumors, respect to other imaging modalities, particularly CT, comparing the percentage of patients identified with positive CT scan showing the percentage of patients identified themselves with positive PET;Secondary Objective: To highlight, in patients diagnosed with blood chemistry (determination of chromogranin positivity) and / or clinic, the number of lesions identified on CT than the number of injuries ``active`` positive PET with 68Ga-DOTANOC and therefore expressing somatostatin receptors.
- Secondary Outcome Measures
Name Time Method